Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
Aab5qSX5mVmxMvGb
